EZH2 and triple-negative breast carcinoma: We found that triple-negative breast carcinoma showed the highest percentage of EZH2 overexpression compared to ER-positive or HER2-positive subtypes, and 88 % (44/50) cases of grade 3 triple-negative breast carcinoma showed uniformly strong EZH2 expression with a multiplicative score of 9.